Biocept

Completing the Answer™

Newly Published Data in Journal of Clinical Pathology Provides Clinical Validation for Biocept's Target Selector™ qPCR Assay to Identify Cancer-Associated Mutations

March 9, 2020

SAN DIEGO, March 9, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of clinical data in the peer-reviewed *Journal of Clinical Pathology* that further validates the Company's Target Selector™ qPCR Assay using "Switch Blocker" technology to identify cancer-related mutations in liquid biopsy samples. The article can be found at https://jcp.bmj.com/content/early/2020/03/04/jclinpath-2019-206381.

Biocept

Completing the Answer™

"Results from this study showed a very high concordance rate between our liquid biopsy testing and tissue biopsy, providing further clinical validation of our Target Selector™ technology," said Veena Singh, M.D.,Biocept's Senior Vice President and Senior Medical Director. "Our clinical testing demonstrates best-in-class detection of alterations down to a single mutant copy, not only in an analytical setting but in a clinical setting as well. Further the ability to inform clinical decision making in a significantly more cost-effective manner potentially affords the healthcare system a highly sensitive and cost-effective option."

The study examined 127 clinical assays for mutations commonly associated with cancer found in the EGFR, BRAF and KRAS genes. Each Target Selector™ assay in the study demonstrated extremely high accuracy, sensitivity and specificity when compared to results obtained from tissue samples, showing a 93%-96% concordance to blinded tissue samples across all assays.

"The continued validation of our technology demonstrates its ability to non-invasively identify biomarkers specific to cancer, and to aid physicians in selecting optimal therapeutic treatments for their patients," said Michael Nall, Biocept's President and Chief Executive Officer. "We are pleased to report that our biomarker testing has been performed in more than 25,000 patients to date, and results from this study further illustrate the enhanced performance of our Target Selector™ technology."

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to inform clinical decision making in a significantly more cost-effective manner, our ability to improve the outcomes of patients diagnosed with cancer, and the potential clinical utility of our proprietary technology platform, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100

Media:
CORE IR
Jules Abraham
julesa@coreir.com
917-885-7378

View original content to download multimedia:http://www.prnewswire.com/news-releases/newly-published-data-in-journal-of-clinical-pathology-provides-clinical-validation-for-biocepts-target-selector-qpcr-assay-to-identify-cancer-associated-mutations-301019347.html

SOURCE Biocept, Inc.